JP2024506940A5 - - Google Patents
Info
- Publication number
- JP2024506940A5 JP2024506940A5 JP2023549820A JP2023549820A JP2024506940A5 JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5 JP 2023549820 A JP2023549820 A JP 2023549820A JP 2023549820 A JP2023549820 A JP 2023549820A JP 2024506940 A5 JP2024506940 A5 JP 2024506940A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150825P | 2021-02-18 | 2021-02-18 | |
| US63/150,825 | 2021-02-18 | ||
| US202163180892P | 2021-04-28 | 2021-04-28 | |
| US63/180,892 | 2021-04-28 | ||
| US202163226037P | 2021-07-27 | 2021-07-27 | |
| US63/226,037 | 2021-07-27 | ||
| US202163285781P | 2021-12-03 | 2021-12-03 | |
| US63/285,781 | 2021-12-03 | ||
| PCT/US2022/016841 WO2022178159A1 (en) | 2021-02-18 | 2022-02-17 | Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506940A JP2024506940A (ja) | 2024-02-15 |
| JP2024506940A5 true JP2024506940A5 (https=) | 2025-02-25 |
| JPWO2022178159A5 JPWO2022178159A5 (https=) | 2025-02-25 |
Family
ID=82931032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549820A Pending JP2024506940A (ja) | 2021-02-18 | 2022-02-17 | Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体を含む組成物及びその使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240309104A1 (https=) |
| EP (1) | EP4294444A4 (https=) |
| JP (1) | JP2024506940A (https=) |
| KR (1) | KR20230157973A (https=) |
| AU (1) | AU2022223420A1 (https=) |
| BR (1) | BR112023016672A2 (https=) |
| CA (1) | CA3207817A1 (https=) |
| CL (1) | CL2023002424A1 (https=) |
| CO (1) | CO2023011969A2 (https=) |
| CR (1) | CR20230436A (https=) |
| DO (1) | DOP2023000162A (https=) |
| EC (1) | ECSP23070237A (https=) |
| GE (2) | GEAP202416596A (https=) |
| IL (1) | IL305312A (https=) |
| JO (1) | JOP20230185A1 (https=) |
| MX (1) | MX2023009622A (https=) |
| PE (1) | PE20231681A1 (https=) |
| TW (1) | TW202246322A (https=) |
| WO (1) | WO2022178159A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102343212B1 (ko) | 2013-03-27 | 2021-12-23 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4637819A1 (en) * | 2022-12-22 | 2025-10-29 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors |
| WO2024173838A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the bile duct |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| KR102417687B1 (ko) * | 2016-05-09 | 2022-07-07 | 브리스톨-마이어스 스큅 컴퍼니 | Tl1a 항체 및 그의 용도 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| WO2021081365A1 (en) * | 2019-10-24 | 2021-04-29 | Prometheus Biosciences, Inc. | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
-
2022
- 2022-02-17 AU AU2022223420A patent/AU2022223420A1/en active Pending
- 2022-02-17 IL IL305312A patent/IL305312A/en unknown
- 2022-02-17 WO PCT/US2022/016841 patent/WO2022178159A1/en not_active Ceased
- 2022-02-17 TW TW111105898A patent/TW202246322A/zh unknown
- 2022-02-17 BR BR112023016672A patent/BR112023016672A2/pt unknown
- 2022-02-17 KR KR1020237031689A patent/KR20230157973A/ko active Pending
- 2022-02-17 JP JP2023549820A patent/JP2024506940A/ja active Pending
- 2022-02-17 MX MX2023009622A patent/MX2023009622A/es unknown
- 2022-02-17 CR CR20230436A patent/CR20230436A/es unknown
- 2022-02-17 PE PE2023002389A patent/PE20231681A1/es unknown
- 2022-02-17 CA CA3207817A patent/CA3207817A1/en active Pending
- 2022-02-17 EP EP22756949.8A patent/EP4294444A4/en active Pending
- 2022-02-17 GE GEAP202416596A patent/GEAP202416596A/en unknown
- 2022-02-17 US US18/546,938 patent/US20240309104A1/en active Pending
- 2022-02-17 GE GEAP202316354A patent/GEAP202316354A/en unknown
-
2023
- 2023-08-09 JO JOJO/P/2023/0185A patent/JOP20230185A1/ar unknown
- 2023-08-16 CL CL2023002424A patent/CL2023002424A1/es unknown
- 2023-08-17 DO DO2023000162A patent/DOP2023000162A/es unknown
- 2023-09-08 CO CONC2023/0011969A patent/CO2023011969A2/es unknown
- 2023-09-14 EC ECSENADI202370237A patent/ECSP23070237A/es unknown